AHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
American Healthcare REIT Inc (AHR) is not a strong buy for a beginner investor with a long-term horizon at this time. While the company has positive catalysts such as strong revenue growth and favorable analyst ratings, the recent insider selling, declining net income, and lack of strong trading signals suggest a cautious approach. The current price trend and technical indicators do not present a compelling entry point for long-term investment.
The stock is showing bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive at 0.212, indicating a bullish trend. However, RSI_6 at 75.39 is in the neutral zone, and the stock is trading near its resistance levels (R1: 53.285). This suggests limited immediate upside potential.
Strong revenue growth of 11.30% YoY in Q4
Achieved 11.8% Same-Store NOI growth in Q4
Analyst ratings are favorable, with an Outperform rating and a $55 price target from BMO Capital.
Positive demand/supply fundamentals in the healthcare REIT sector.
Insiders are selling, with a 148.13% increase in selling activity over the last month.
Net income dropped significantly by -133.91% YoY in Q4
EPS also dropped by -128.57% YoY, indicating profitability challenges.
No significant hedge fund activity or congress trading data to support confidence.
In Q4 2025, revenue increased by 11.30% YoY to $604.08 million, and gross margin improved by 5.73% YoY to 20.49. However, net income dropped by -133.91% YoY to $10.78 million, and EPS declined by -128.57% YoY to $0.06, reflecting profitability challenges.
Analysts have a positive outlook on the stock. BMO Capital initiated coverage with an Outperform rating and a $55 price target, citing strong demand/supply fundamentals. Truist maintained a Buy rating but lowered the price target to $52, reflecting cautious optimism in the REIT sector.
